A trial looking at ixazomib for people with myeloma that has come back (Myeloma XII ACCoRd)

This trial was for people who had already had a stem cell transplant and who had no sign of their myeloma for at least 12 months before it came back (relapsed).

The people taking part were fit and healthy enough to have another stem cell transplant. It was looking at a type of targeted cancer drug called ixazomib. Ixazomib is pronounced icks-azz-owe-mib.

The trial was open for people to join between 2017 and 2022. The team presented some of the results at a conference in 2023. They looked at how safe ixazomib was and how well it worked for people after their second stem cell transplant.

The research team plan to publish more results at a later date. We will add longer term results when they are available.

This trial was supported by Cancer Research UK.